Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate

Prothena Corporation plc PRTA announced topline data from the Phase 1 single ascending dose (SAD) study for PRX005 for Alzheimer's disease.
PRX005 is one of three global neuroscience research and development programs in collaboration between Prothena and Bristol Myers Squibb & Co BMY.
Study participants received a single dose of PRX0005 or placebo intravenously (IV) and were followed for up to two months. The data exhibited that all three dose-level cohorts of PRX005 were generally safe and well tolerated.
None of the treatment-emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters.
PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints. Plasma drug concentrations of PRX005 increased in a dose-proportional manner.
Furthermore, PRX005 exposure in cerebrospinal fluid (CSF) was measured in the high-dose cohort and based on the robust exposure of PRX005 in the CSF.
PRX005 had a desirable immunogenicity profile with no persistent PRX005-induced antidrug antibodies observed.
Topline results from the Phase 1 MAD trial are expected by year-end 2023.
Price Action: PRTA shares are down 3.55% at $54.64 on the last check Wednesday.